302.41
price down icon0.79%   -2.40
after-market アフターアワーズ: 302.41
loading
前日終値:
$304.81
開ける:
$301.85
24時間の取引高:
488.74K
Relative Volume:
0.84
時価総額:
$13.64B
収益:
$2.99B
当期純損益:
$1.21B
株価収益率:
12.07
EPS:
25.06
ネットキャッシュフロー:
$1.13B
1週間 パフォーマンス:
+7.26%
1か月 パフォーマンス:
+2.69%
6か月 パフォーマンス:
-14.51%
1年 パフォーマンス:
-6.07%
1日の値動き範囲:
Value
$299.44
$307.06
1週間の範囲:
Value
$272.12
$307.49
52週間の値動き範囲:
Value
$266.98
$417.81

United Therapeutics Corp Stock (UTHR) Company Profile

Name
名前
United Therapeutics Corp
Name
セクター
Healthcare (1161)
Name
電話
(301) 608-9292
Name
住所
1000 SPRING ST, SILVER SPRING, MD
Name
職員
1,305
Name
Twitter
Name
次回の収益日
2024-10-30
Name
最新のSEC提出書
Name
UTHR's Discussions on Twitter

UTHR を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
302.41 13.79B 2.99B 1.21B 1.13B 25.06
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
146.50 65.05B 9.29B 2.52B 2.28B 5.57
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.27 44.85B 29.98B 958.27M 5.31B 0.2964
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.25 41.71B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
16.01 18.02B 16.54B -1.64B 749.00M -1.45

United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-06-02 開始されました Cantor Fitzgerald Overweight
2025-04-25 ダウングレード Wells Fargo Overweight → Equal Weight
2025-04-21 アップグレード BofA Securities Underperform → Neutral
2024-07-11 ダウングレード Morgan Stanley Overweight → Equal-Weight
2024-02-12 アップグレード Goldman Sell → Neutral
2024-02-05 開始されました Leerink Partners Outperform
2023-12-08 開始されました Wells Fargo Overweight
2022-12-06 開始されました UBS Buy
2022-12-05 開始されました Goldman Sell
2022-10-11 開始されました Morgan Stanley Overweight
2022-09-20 繰り返されました BofA Securities Underperform
2022-09-19 再開されました Wedbush Outperform
2022-02-11 開始されました BTIG Research Neutral
2021-07-14 アップグレード Argus Hold → Buy
2021-04-26 再開されました Credit Suisse Outperform
2021-02-01 アップグレード H.C. Wainwright Neutral → Buy
2020-09-14 再開されました JP Morgan Overweight
2020-06-25 繰り返されました H.C. Wainwright Neutral
2020-03-10 アップグレード Jefferies Hold → Buy
2020-02-27 アップグレード Cowen Market Perform → Outperform
2020-01-31 アップグレード JP Morgan Neutral → Overweight
2019-12-03 開始されました BofA/Merrill Underperform
2019-08-01 アップグレード Jefferies Underperform → Hold
2019-08-01 アップグレード Ladenburg Thalmann Neutral → Buy
2019-07-01 アップグレード Credit Suisse Neutral → Outperform
2019-05-17 アップグレード UBS Sell → Neutral
2019-05-09 アップグレード Credit Suisse Underperform → Neutral
2018-10-12 アップグレード Standpoint Research Hold → Buy
2018-08-08 ダウングレード Credit Suisse Neutral → Underperform
2018-04-03 アップグレード Credit Suisse Underperform → Neutral
2018-02-22 繰り返されました Barclays Underweight
2018-01-18 再開されました Credit Suisse Underperform
2017-12-27 繰り返されました Wedbush Outperform
2017-04-27 繰り返されました Wedbush Outperform
2017-03-30 開始されました UBS Sell
2017-03-16 開始されました Credit Suisse Underperform
すべてを表示

United Therapeutics Corp (UTHR) 最新ニュース

pulisher
10:26 AM

MannKind (MNKD) Q2 Revenue Rises 6% - The Motley Fool

10:26 AM
pulisher
Aug 04, 2025

H.C. Wainwright Lowers PT on United Therapeutics Corporation (UTHR) to $400 From $425, Keeps a Buy Rating - Insider Monkey

Aug 04, 2025
pulisher
Aug 01, 2025

United Therapeutics Announces $1B Accelerated Share Repurchase Program. - AInvest

Aug 01, 2025
pulisher
Aug 01, 2025

United Therapeutics’ PAH Study Update: Implications for Investors - TipRanks

Aug 01, 2025
pulisher
Aug 01, 2025

United Therapeutics’ Inhaled Treprostinil Study: A Potential Game-Changer for IPF Treatment - TipRanks

Aug 01, 2025
pulisher
Aug 01, 2025

United Therapeutics Advances in Pulmonary Fibrosis Treatment with Phase 3 Study - TipRanks

Aug 01, 2025
pulisher
Aug 01, 2025

United Therapeutics (UTHR) Launches $1B Stock Buyback Program - GuruFocus

Aug 01, 2025
pulisher
Aug 01, 2025

United Therapeutics Corporation (NASDAQ:UTHR) Q2 2025 Earnings Call Transcript - Insider Monkey

Aug 01, 2025
pulisher
Aug 01, 2025

United Therapeutics stock jumps on $1 billion share repurchase plan - Investing.com

Aug 01, 2025
pulisher
Aug 01, 2025

United Therapeutics Launches $1 Bln Stock Buyback - Nasdaq

Aug 01, 2025
pulisher
Aug 01, 2025

United Therapeutics Unveils Massive $1B Stock Buyback Plan in Strategic Financial Move - Stock Titan

Aug 01, 2025
pulisher
Aug 01, 2025

Pulmonary Arterial Hypertension Drug Market to See Booming - openPR.com

Aug 01, 2025
pulisher
Aug 01, 2025

What is the dividend policy of United Therapeutics Corporation stockFree Stock Alerts For Every Investor - Jammu Links News

Aug 01, 2025
pulisher
Aug 01, 2025

United Therapeutics Reports Record Q2 2025 Financial Results - The Globe and Mail

Aug 01, 2025
pulisher
Jul 31, 2025

BTIG Lowers Liquidia (LQDA) PT to $40, Potential for Yutrepia Launch Remains a Focus - Insider Monkey

Jul 31, 2025
pulisher
Jul 31, 2025

United Therapeutics Reports Record Revenue and Growth - TipRanks

Jul 31, 2025
pulisher
Jul 31, 2025

H.C. Wainwright lowers United Therapeutics stock price target on Tyvaso competition concerns - Investing.com Nigeria

Jul 31, 2025
pulisher
Jul 31, 2025

United Therapeutics Corp (UTHR) Q2 2025 Earnings Call Highlights: Record Revenue and Strategic ... By GuruFocus - Investing.com Canada

Jul 31, 2025
pulisher
Jul 31, 2025

United Therapeutics: Q2 Earnings Snapshot - Greenwich Time

Jul 31, 2025
pulisher
Jul 31, 2025

Decoding United Therapeutics Corp (UTHR): A Strategic SWOT Insight - GuruFocus

Jul 31, 2025
pulisher
Jul 30, 2025

United Therapeutics’ Phase 3 Study on Inhaled Treprostinil: A Potential Game-Changer for IPF Treatment - TipRanks

Jul 30, 2025
pulisher
Jul 30, 2025

United Therapeutics Stock Slides On Q2 Earnings: The Details - 富途牛牛

Jul 30, 2025
pulisher
Jul 30, 2025

Earnings call transcript: United Therapeutics Q2 2025 misses EPS, stock drops - Investing.com Canada

Jul 30, 2025
pulisher
Jul 30, 2025

United Therapeutics’ Promising Phase 3 Study on Inhaled Treprostinil for Pulmonary Fibrosis - TipRanks

Jul 30, 2025
pulisher
Jul 30, 2025

Here's Why United Therapeutics (UTHR) is a Strong Growth Stock - Yahoo Finance

Jul 30, 2025
pulisher
Jul 30, 2025

Compared to Estimates, United Therapeutics (UTHR) Q2 Earnings: A Look at Key Metrics - Nasdaq

Jul 30, 2025
pulisher
Jul 30, 2025

United Therapeutics Q2 2025 slides: Revenue up 12% as Tyvaso drives growth - Investing.com Nigeria

Jul 30, 2025
pulisher
Jul 30, 2025

United Therapeutics Logs Growth And Launches Big Buyback - Finimize

Jul 30, 2025
pulisher
Jul 30, 2025

United Therapeutics (UTHR) Misses Q2 Earnings Estimates - Yahoo Finance

Jul 30, 2025
pulisher
Jul 30, 2025

United Therapeutics misses Q2 earnings expectations By Investing.com - Investing.com South Africa

Jul 30, 2025
pulisher
Jul 30, 2025

United Therapeutics misses Q2 earnings expectations - Investing.com

Jul 30, 2025
pulisher
Jul 30, 2025

United Therapeutics Corporation Reports Record Second Quarter 2025 Financial Results - TradingView

Jul 30, 2025
pulisher
Jul 30, 2025

UNITED THERAPEUTICS Corp SEC 10-Q Report - TradingView

Jul 30, 2025
pulisher
Jul 30, 2025

United Therapeutics earnings missed by $0.94, revenue fell short of estimates - Investing.com

Jul 30, 2025
pulisher
Jul 30, 2025

United Therapeutics Delivers Triple Win: Record $799M Revenue, $1B Buyback, and Major Pipeline Progress - Stock Titan

Jul 30, 2025
pulisher
Jul 30, 2025

United Therapeutics enters $1B accelerated share repurchase program - MSN

Jul 30, 2025
pulisher
Jul 29, 2025

United Therapeutics Corporation (UTHR) Launches First UKidney Human Trial - MSN

Jul 29, 2025
pulisher
Jul 29, 2025

United Therapeutics’ Promising IPF Treatment Study: A Market Game-Changer? - The Globe and Mail

Jul 29, 2025
pulisher
Jul 29, 2025

Preview: United Therapeutics's Earnings - 富途牛牛

Jul 29, 2025
pulisher
Jul 29, 2025

Bleecker Street Research short United Therapeutics, long Liquidia - TipRanks

Jul 29, 2025
pulisher
Jul 29, 2025

Published on: 2025-07-29 12:41:34 - metal.it

Jul 29, 2025
pulisher
Jul 29, 2025

United Therapeutics Earnings Announcement and Market OutlookNews and Statistics - IndexBox

Jul 29, 2025
pulisher
Jul 29, 2025

Is There Enough Volume to Lift United Therapeutics CorporationTriple Return Setup With Risk Control Explained - metal.it

Jul 29, 2025
pulisher
Jul 29, 2025

UBS Trims Price Target but Stays Bullish on United Therapeutics (UTHR) - MSN

Jul 29, 2025
pulisher
Jul 29, 2025

Why United Therapeutics Corporation stock attracts strong analyst attentionWeekly Top Gainers Forecast Watchlist Released - metal.it

Jul 29, 2025
pulisher
Jul 29, 2025

What institutions are buying United Therapeutics Corporation stock nowEarnings Play Trade Plan With Alerts Shared - metal.it

Jul 29, 2025
pulisher
Jul 28, 2025

What To Expect From United Therapeutics’s (UTHR) Q2 Earnings - ca.finance.yahoo.com

Jul 28, 2025
pulisher
Jul 28, 2025

ROSEN, A LEADING LAW FIRM, Encourages 3D Systems Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.

Jul 28, 2025
pulisher
Jul 28, 2025

How many analysts rate United Therapeutics Corporation as a “Buy”Entry Signal Forecasts With Low Risk - jammulinksnews.com

Jul 28, 2025

United Therapeutics Corp (UTHR) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$128.43
price up icon 0.03%
drug_manufacturers_specialty_generic RDY
$13.33
price down icon 2.49%
$8.75
price down icon 2.56%
$16.01
price up icon 1.91%
$13.95
price down icon 1.76%
大文字化:     |  ボリューム (24 時間):